Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Cediranib Filing Withdrawal: CHMP Had Two Major Issues

Executive Summary

European filing for ovarian cancer candidate cediranib was undone by differences in opinion between AstraZeneca and EMA's CHMP advisory committee in two key areas – the clinical benefit, and compliance with GCP.

Advertisement

Related Content

“Excellence In Execution” Is Key To AstraZeneca’s Bid To Be An Oncology Leader

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel